Prostate cancer: The problem of prognostic factors

American Journal of Clinical Pathology

Volumn 106, Issue 4 SUPPL. 1, 1996, Pages

  Murphy, William M ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cancer; Carcinoma; Prognosis; Prostate

Indexed keywords

CANCER DIAGNOSIS; CLINICAL PRACTICE; HUMAN; PATIENT EDUCATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; REVIEW;

HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0029745050     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-385.
2. Wingo PA, Tong T, Bolden S. Cancer Statistics, 1995. CA Cancer J Clin 1995;45:8-30.
3. Larsen MP, Carter HB, Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. J Urol 1991;146:1059-1063.
4. Whitmore WF Jr. Conservative approaches to the management of localized prostatic cancer. Cancer 1993;71:970-975.
5. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990;144:1180-1184.
6. Adolfsson J, Carstensen J. Natural course of clinically localized prostate adenocarcinoma in men less than 70 year old. J Urol 1991;146:96-98.
7. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993;149:516-518.
8. Stamey TA, McNeal JE: Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey, TA, Vaughan ED Jr. Campbell's Urology, ed 6. Philadelphia: WB. Saunders Co, 1992, pp 1182-1186.
9. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the prostate cancer working group. Arch Pathol Lab Med 1995;119:1122-1126.
10. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer 1993;71:3582-3593.
11. Albertsen PC, Fryback DG, Storer BE, et al Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995:274:626-631.
12. Brawn P. Histologic features of metastatic prostate cancer. Hum Pathol 1992;23:267-272.
13. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: A study of 94 cases with extended follow up. J Urol 1986;136:837-839.
14. Johansson J-E, Sigurdsson T, Holmberg L, Bergström R. Erythrocyte sedimentation rate as a tumore marker in human prostatic cancer: An analysis of prognostic factors in 300 population-based consecutive cases. Cancer 1992;70:1556-1563.
15. Danella JF, dekernion JB, Smith RB, Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 1993;149: 1488-1491.
16. Adolfsson J. Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol 1993;149:326-328.
17. Rosen MA, Goldstone L, Lapin S, et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992;148:331-337.
18. Epstein, JI, Carmichael M, Walsh, PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade, and margins of resection to prognosis. J Urol 1993;149:1040-1045.
19. Keetch DW, Humphrey P, Stahl D, et al. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154:347-351.
20. Oesterling JE, Epstein JI, Walsh PC. Long-term autopsy findings following radical prostatectomy. Urology 1987;29:584-588.
21. Stein A, dekernion JB, Smith RB, et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147: 942-946.
22. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up Am J Surg Pathol 1996;20:286-292.
23. Zincke H, Bergstralh EJ, Larson-Keller JJ, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer (suppl 1) 1992;70:311-323.
24. Humphrey PA, Walther PJ. Adenocarcinoma of the prostate: Part II: tissue prognosticators. Am J Clin Pathol 1993;100:256-269.
25. Aihara M, Scardino PT, Truong LD, et al. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995;75:522-529.
26. Foster CS, McLoughlin J, Bashir I, Abel PD. Markers of the metastatic phenotype in prostate cancer. Hum Pathol 1992;23:381-394.
27. Fujikawa K, Sasaki M, Aoyama T, et al. Prognostic criteria in patients with prostate cancer: correlation with volume weighted mean nuclear volume. J Urol 1995;154:2123-2127.
28. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26:824-828.
29. Hughes JH, Cohen MB, Robinson RA. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma. Mod Pathol 1995;8:462-466.
30. Aprikian AG, Zhang Z-F, Fair WR. Prostate adenocarcinoma in men younger than 50 years: A retrospective review of 151 patients. Cancer 1994;74:1768-1777.
31. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
32. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Cancer 1993;73:1709-1725.
33. Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease-free survival among patients with prostate cancer. Cancer 1992;70:161-168.
34. Brawn PN, Johnson EH, Kuhl DL, et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993;71:2569-2573.
35. McNeal JE. Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 1992;23:258-266.
36. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with five years follow-up. J Urol 1993;149:1478-1481.
37. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-1548.
38. Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: A review of current results. Int J Cancer 1994;58:211-216.
39. Shankey TV, Kallioniemi OP, Koslowski JM, et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 1993;14:497-500.
40. Tribukait B. Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: clinical research and application. Eur Urol 1993;23:64-76.
41. McIntire TL, Murphy WM, Coon JS, et al. The prognostic value of DNA ploidy combined with histologic substaging for incidental carcinoma of the prostate gland. Am J Clin Pathol 1988;89: 370-373.
42. Periosteum LP, Schaeffer H, Feldman JG, et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995;73:302-305.
43. Miyamoto KK, McSherry SA, Dent G, et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993;149:1015-1019.
44. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: recent findings and new concepts. Cancer 1995;75: 1850-1859.
45. Cohen MK, Arber DA, Coffield S. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-1903.